Aditxt Inc is a biotech company focused on enhancing the immune system through innovative technologies designed to promote immune tolerance. The company seeks to develop therapies that can help manage and treat immune-related diseases by leveraging its proprietary platform to create customized solutions. Aditxt's research and development efforts aim to address a range of immunological disorders, potentially transforming the landscape of immunotherapy and improving patient outcomes through better immune system management. Read More
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt”, or the “Company”), a social innovation platform accelerating promising health innovations, today announced an update on its wholly owned subsidiary Adimune, Inc. (“Adimune”), which is pioneering a DNA-based therapeutic platform designed to reprogram the immune system. Adimune’s intellectual property portfolio now includes 96 granted and 22 pending patents that are owned or exclusively licensed by Aditxt, supporting the company’s strategy to address the global autoimmune therapeutics market, which is estimated at over $160 billion by 2030.
Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, announced today that it has signed a custody agreement with Crypto.com, a global leader in digital asset platforms, to establish a custodial crypto account. The agreement is a foundational step in the broader planned rollout of bitXbio™—Aditxt’s crypto-native social platform bridging Fintech and Biotech.
Aditxt (NASDAQ: ADTX), announced that Saundra Pelletier, CEO of Evofem Biosciences—its pending acquisition target—has received the Trailblazing Female Founders Award at the 2025 STIMULATE Conference in Nashville. Recognized for advancing women’s sexual and reproductive health, Pelletier leads Evofem, the developer of hormone-free contraceptive PHEXXI(R) and SOLOSEC(R), an oral treatment for bacterial vaginosis and trichomoniasis. The award coincides with Say Vagina Month, a campaign launched by Evofem to normalize open, accurate conversations around vaginal health. Aditxt expects to complete its acquisition of Evofem in the second half of 2025.
Aditxt (NASDAQ: ADTX), a social innovation platform focused on accelerating health innovations, announced that its subsidiary Pearsanta, Inc. has engaged Spartan Capital Securities, LLC as lead underwriter for its planned Initial Public Offering. The proposed IPO is intended to support the clinical validation and commercial rollout of Pearsanta’s early cancer and disease detection tests powered by its Mitomic mitochondrial DNA platform and CLIA-certified, CAP-accredited laboratory infrastructure. CEO Amro Albanna said the IPO aligns with Aditxt’s Acquire, Build, and Capitalize strategy, positioning Pearsanta to expand market access and deliver life-saving diagnostics through early detection.
Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc., (“Pearsanta”) has engaged Spartan Capital Securities, LLC (“Spartan”) as lead underwriter for its planned Initial Public Offering (”IPO”). This marks an important milestone in Aditxt’s Acquire, Build, and Capitalize (“ABC”) strategy, which is designed to accelerate the growth of innovative health companies.
Aditxt (NASDAQ: ADTX), a social innovation platform advancing health technologies, announced that its subsidiary Pearsanta, Inc. has been invited to submit a full proposal for the U.S. Department of Defense’s OCRP Pilot Award. The proposal supports Pearsanta’s Mitomic(R) Ovarian Test (MOT(TM)), a novel blood-based diagnostic aimed at early ovarian cancer detection. Pearsanta’s pre-proposal was favorably reviewed for scientific merit and innovation. If awarded, the grant would provide up to $350,000 over two years. The company plans to validate the test in a multi-center clinical study and prepare for commercial launch as a laboratory-developed test.
Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, is pleased to announce that its subsidiary, Pearsanta, Inc. (“Pearsanta”), has received an invitation to submit a full proposal for the Congressionally Directed Medical Research Program’s (CDMRP) Ovarian Cancer Research Program (“OCRP”) Pilot Award, funded through the U.S. Department of Defense (Funding Opportunity Number: HT942525OCRPPA) for its Mitomic® Ovarian Test (“MOT™”), a novel blood-based diagnostic for ovarian cancer.
Aditxt (NASDAQ: ADTX), a social innovation platform advancing health solutions, will host a livestream on July 22, 2025, at 1:00 p.m. ET to highlight its autoimmune therapeutics subsidiary, Adimune Inc. The event, hosted by Jack Marks of Wall Street Reporter, will feature Aditxt Co-founder and CEO Amro Albanna discussing Adimune’s innovative approach, upcoming milestones, and opportunities in the growing autoimmune disease market.
Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced a live discussion focused on its wholly owned subsidiary Adimune™, Inc. (“Adimune™”), which is advancing therapeutics designed to address autoimmune diseases.
Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced its bitXbio (pronounced “bit by bio”) Plan, a next-generation capitalization and monetization public-market strategy integrating Bitcoin (BTC) in support of its biotech commercialization efforts. The initiative will be anchored by a Bitcoin-backed treasury strategy that was recently approved by its board of directors, aimed at expanding Aditxt’s capital ecosystem and aligning its enterprise value (EV) with projected monetization opportunities starting in 2026.
Aditxt (NASDAQ: ADTX), a social innovation platform advancing health breakthroughs, announced that Co-founder and CEO Amro Albanna will present at the NEXT SUPER STOCK livestream hosted by Wall Street Reporter on June 26, 2025, at 1:00 p.m. ET. Albanna will outline Aditxt’s innovation acceleration model, provide updates on its autoimmunity and early cancer detection programs, and share the latest on the company’s pending acquisition of Evofem Biosciences, Inc.
Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, is pleased to announce that Co-founder and CEO Amro Albanna will be presenting at Wall Street Reporter’s NEXT SUPER STOCK livestream event on June 26, 2025 at 1:00 p.m. ET.
